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A B S T R A C TObjective: Uncontrolled hypertension (HTN) results in strokes, myo-
cardial infarction (MI), and other complications, which are the leading
cause of disability, death, and severe economic consequence. We
conducted an economic evaluation to determine the costs and
quality-adjusted life-years (QALYs) associated with amlodipine (Nor-
vasc) and the angiotensin II receptor blockers (ARBs) in preventing
stroke and MI among Chinese HTN patients. Methods: A cost-utility
analysis was conducted from the third-party payer perspective. A
Markov model was constructed to estimate 5-year costs and health
consequences of amlodipine and valsartan. Effectiveness data were
based on a published meta-analysis. Utility data were retrieved from
the published literature. Costs of MI were retrieved from China Health
Statistics Yearbook. Costs of stroke were obtained from retrospective
chart review and follow-up interviews in Chinese tertiary hospitals.
Costs included costs of drugs, direct medical costs of HTN manage-
ment, stroke/MI treatment, and follow-up management. Discountingsee front matter Copyright & 2013, International
r Inc.
.1016/j.vhri.2013.01.005
st: The authors have indicated that they have no
yin@yahoo.com.
ondence to: Hongjun Yin, Philadelphia College of Orate used for costs and QALYs was 3%. Results: Total direct medical
and drug costs of amlodipine and valsartan (ARB) users were
f111,731,716 and f132,058,611, respectively; total QALYs of amlodipine
and valsartan users were 30,648.5 and 30,520.8, respectively. Amlodi-
pine is dominant with lower costs and higher QALYs. This demon-
strated that compared with valsartan, amlodipine is a cost-saving
therapy with better QALY outcome. When irbesartan data were used
in the comparison, the magnitude of cost saving changed but the
overall conclusion remained the same. Conclusion: Amlodipine is a
cost-saving therapy compared with ARBs in preventing stroke and MI
for Chinese HTN patients.
Keywords: amlodipine, angiotensin II receptor blockers, China, cost-
effectiveness, hypertension, irbesartan.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Hypertension (HTN), or high blood pressure, now defined as systolic
blood pressure of more than 140 mmHg and diastolic blood pressure
of more than 90 mm Hg, is attributed as the leading cause of
cardiovascular mortality by the World Health Organization. In 2000,
it was estimated that 972 million adults or 26.4% of the adult
population had HTN worldwide [1]. The number of adults with
HTN in 2025 is predicted to increase by 60% to 1.56 billion [2]. In
China, there were approximately 153 million people with HTN in
2005, leading to 1.27 million premature deaths from cardiovascular
diseases and more than 2 million deaths in total [2]. Among Chinese
people with HTN, approximately 19% received pharmacological
treatment, but only about 25% of the treated patients had their blood
pressure well controlled [3]. The direct medical cost of HTN was f20.2
billion, according to 2003 National Health Services Survey [4].Uncontrolled HTN may result in various complications (e.g.,
strokes, heart failure, myocardial infarction [MI], and peripheral
vascular disease), which are the major causes of morbidity and
mortality. About 54% of stroke, 47% of ischemic heart disease,
and 25% of other cardiovascular diseases worldwide were caused
by elevated blood pressure [5]. In East Asia and the Pacific, deaths
and disability-adjusted life-years of hypertensive patients attrib-
uted to stroke were the highest among all cardiovascular end
points [5]. The incidence of stroke increases in proportion to both
systolic and diastolic blood pressures. Most ischemic strokes
occur in individuals with pre-HTN or stage 1 HTN [6]. The
incidence of ischemic or hemorrhagic stroke is reduced substan-
tially by adequate treatment of HTN [6]. A slight reduction in
blood pressure over a time period of 3 to 4 years among
moderately complicated hypertensive patients lowers the inci-
dence of all cardiac events by 35% [7].Society for Pharmacoeconomics and Outcomes Research (ISPOR).
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cause of death, responsible for 4.4 million (9%) of the total 50.5
million deaths each year [8]. In China, recent epidemiologic
studies confirmed that stroke was the leading cause of adult
disability, and the second commonest cause of death, with an
incidence more than fivefold that of MI [9]. The direct medical
cost of stroke was f24.3 billion, according to 2003 National Health
Services Survey [4]. HTN is the single most important risk factor
for all types of strokes including both ischemic and hemorrhagic
[10]. The association between high blood pressure and stroke has
been evident for many years. Meta-analysis of randomized
controlled trials showed that lowering of blood pressure was
associated with a 30% to 40% reduction in stroke risk [11]. To
prevent the future occurrence of stroke among hypertensive
patients, it is critical to keep blood pressure under good control
with effective pharmacological treatments.
There are many classes of antihypertensive drugs in the
market with different mechanisms of action. Among the most
important and most widely used are the thiazide diuretics, the
angiotensin-converting enzyme inhibitors , the calcium channel
blockers (CCBs), the beta blockers, and the angiotensin II receptor
blockers (ARBs). ARBs, such as losartan and valsartan, are a
newer and safer class of antihypertensive agents. They are
primarily used for the treatment of HTN when the patient is
intolerant of angiotensin-converting enzyme inhibitor therapy,
because of their affirmative efficacy and better tolerance. Clinical
trial data showed that ARBs did not adversely affect kidney
function, even in the presence of chronic renal insufficiency
[12]. Because of their short half-lives, however, many of the ARBs
may require twice-daily dosing in some patients to keep the
blood pressure under control, which would substantially increase
the cost [12].
CCBs is another widely used type of antihypertensive. They
account for approximately 60%, with an upward trend of all
antihypertensive drugs prescribed by clinicians [13–15]. Dihydro-
pyridine CCBs, for example, amlodipine (Norvasc) and aranidi-
pine, make up more than 85% of all CCBs prescribed [16]. Their
advantages over other types of antihypertensive drugs include
good tolerance and lack of withdrawal syndrome. They can also
be taken together with drugs from other groups such as anti-
biotics, nonsteroidal anti-inflammatory drugs, and glucose-
lowering drugs. CCBs are especially suitable for the treatment
of senior hypertensive patients with stable angina pectoris or
diabetes mellitus. By using CCBs, the risk of fatal stroke can be
reduced by 44% to 55% and the risk of stroke-related dementia
can be reduced by 50% [17]. Compared with all the other
antihypertensive drugs, CCBs have the lowest drug discontinua-
tion and switching [14].Fig. 1 – Structure of the Markov moNorvasc (amlodipine besylate), the besylate salt of amlodi-
pine, is a long-acting CCB of the third generation. It is the most
frequently prescribed drug in the CCB group, because of a
number of its favorable pharmacodynamic and pharmacokinetic
properties: high bioavailability, long half-life, and longer duration
of action, which allows patients to take the medication once
daily. During treatment with Norvasc in hypertensive patients of
different degrees of severity, the risk of cardiovascular events,
including the development of cerebral circulatory disorders,
gradually decreases [18].
In a meta-analysis, Wang et al. [19] demonstrated that
Norvasc is superior to ARBs in the prevention of stroke and MI
in HTN patients. On the basis of the results from that analysis,
we conducted an economic evaluation to determine the long-
term cost-effectiveness of Norvasc from the payer perspective
given its association with the reduction in stroke events and
associated averted costs when compared with ARBs. In addition,
the quality-adjusted life-years (QALYs) gained under each ther-
apeutic strategy was estimated over a 5-year period.Methods
Overview
Using Excel, a Markov model was constructed to conduct the
cost-effectiveness analysis comparing Norvasc and the ARBs. The
model evaluated a population of HTN patients in the Chinese
setting.
We conducted a thorough review on inpatient cost, cost of
home health care, rehabilitation costs after discharge, and
indirect cost associated with stroke and MI treatment. Given
the limited cost data available in the literature, a retrospective
chart review of patients with stroke in three tertiary Chinese
hospitals and a follow-up telephone interview on the patients
after discharge were carried out to determine the acute hospita-
lization costs associated with stroke and 1-year follow-up costs
poststroke hospitalization discharge.
Clinical data were obtained from the meta-analysis study by
Wang et al. [19], studies cited by Wang et al., and the retro-
spective chart review in the three tertiary Chinese hospitals.
The analysis was conducted from the perspective of the third-
party health care payer, with costs expressed in 2011-2012 prices.
Costs and outcomes were discounted at 3% per year.
Model Structure
A cost-effectiveness analysis based on Markov model was con-
structed to explore the economic benefits and QALY gaineddel. MI, myocardial infarction.
Table 1 – Summary of input parameters applied in the base-case model.
Variables Value Source
Baseline patient characteristics
Age (y) 65 Assumption
Sex 50% men Assumption
Stroke risk
Male ARB users 11.3/1,000 PY [22] (Estimated on the basis of the incidence rate and gender distribution in the
VALUE trial, and gender-specific risk ratio in the Chinese population)
Female ARB users 8.2/1,000 PY [22] (Estimated on the basis of the incidence rate and gender distribution in the
VALUE trial, and gender-specific risk ratio in the Chinese population)
Relative risk for stroke
(amlodipine vs. ARBs)
0.84 [19]
MI risk
Male ARB users 15.1/1,000 PY [22] (Estimated on the basis of the incidence rate and gender distribution in the
VALUE trial, and gender-specific risk ratio in the Chinese population)
Female ARB users 6.1/1000 PY [22] (Estimated on the basis of the incidence rate and gender distribution in the
VALUE trial, and gender-specific risk ratio in the Chinese population)
Relative risk for MI (amlodipine
vs. ARBs)
0.83 [19]
Mortality risk
Among stroke events 27.2% [20]
Among MI events 6.3% [21]
Stroke survivors vs. general
population
2.3 [20]
MI survivors vs. general
population
2.3 [21]
Annual cost of each health state
Alive without MI/stroke f100.00 Based on the telephone follow-up on patients discharged from x tertiary hospitals
Fatal stroke f11,836.30 Based on the telephone follow-up on patients discharged from x tertiary hospitals
Nonfatal stroke (year 1) f35,479.50 Based on the telephone follow-up on patients discharged from x tertiary hospitals
Poststroke (year 2þ) f3,547.95 Assume 10% of year 1 cost
MI (year 1, fatal or nonfatal) f26,422.35 [23] (assuming 50% surgery and 50% nonsurgery treatment)
Post-MI (year 2þ) f2,642.24 Assume 10% of year 1 cost
ARBs annual cost (valsartan) f2,388.00 [24]
Amlodipine annual cost f1,987.00 [24]
Other-cause death f1,000.00 Estimation
Quality of life of each health state
Alive without MI/stroke
(55–59 y, male)
0.77 [25]
Alive without MI/stroke
(55–59 y, female)
0.75 [25]
Alive without MI/stroke
(60–64 y, male)
0.75 [25]
Alive without MI/stroke
(60–64 y, female)
0.73 [25]
Alive without MI/stroke
(65–69 y, male)
0.73 [25]
Alive without MI/stroke
(65–69 y, female)
0.70 [25]
Alive without MI/stroke
(70–74 y, male)
0.70 [25]
Alive without MI/stroke
(70–74 y, female)
0.69 [25]
Nonfatal stroke (year 1) 0.50 [26]
Poststroke (year 2þ) 0.63 [26]
Nonfatal MI (year 1) 0.70 [26]
Post-MI (year 2þ) 0.80 [26]
Annual discount rate
On costs 3%
On QALYs 3%
ARB, angiotensin II receptor blocker; MI, myocardial infarction; PY, person year; QALY, quality-adjusted life-year.
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Table 3 – Results of base-case analysis comparing
ARBs and amlodipine over 5-y time horizon.
Total cost (f) Total QALY
Amlodipine (Norvasc) 105,757,181.9 29,019.4
ARBs 125,021,803.2 28,900.7
Difference 19,264,622.3 118.7
ARBs, angiotensin II receptor blockers; QALY, quality-adjusted life-
year.
Table 2 – Age-specific mortality rate in general
Chinese population [21].
Age (y) Mortality
Men (%) Women (%)
55–59 1.06 0.66
60–64 1.79 1.14
65–69 2.96 1.91
70–74 5.10 3.41
VA L U E I N H E A LT H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 7 5 – 8 078associated with the stroke and MI prevention when Norvasc was
used in comparison with ARBs. The Markov model considered
costs and outcomes within 5 years by using annual cycles. We
chose the time span of 5 years given that social security
authorities at provincial or municipal governments in China
use that as their frame for budget planning. Six health states
were defined in the model: alive without stroke/MI, stroke,
poststroke, MI, post-MI, and death (Fig. 1). The model was based
on 10,000 patients in the amlodipine and ARBs arms, respectively.
The model was populated with the following data: 1) inci-
dence of stroke and MI in the general HTN population,
amlodipine-treated population, and ARBs-treated population; 2)
costs of clinical management of HTN and its associated out-
comes; 3) costs of drugs and drug-associated side effects; 4) unit
costs of stroke and MI acute treatment and the costs of long-term
follow-up; and 5) other relevant data required for the model.Table 4 – Total discounted cost, quality-adjusted life-yea
(ICERs) for the sensitivity analyses in 2011–2012 Chines
Total cost (f)
Amlodipine ARBs
Base case 105,757,180.9 125,021,803.2
ARB irbesartan (f1950) 105,757,180.9 107,837,911.9
Gender males 30% 104,192,276.6 123,062,115.9
Gender males 40% 104,992,424.7 124,039,783.0
Gender males 60% 106,625,875.8 125,996,463.8
Gender males 70% 107,439,945.0 126,847,406.7
Cohort age at 55 y 109,838,524.0 129,859,467.0
Cohort age at 60 y 108,270,116.4 127,983,091.7
Cohort age at 70 y 101,297,725.0 119,685,447.8
Discount 1% 113,798,954.4 134,493,297.9
Discount 2% 109,642,802.1 129,598,341.9
Discount 4% 102,120,670.3 120,738,479.1
Discount 5% 98,713,797.6 116,725,458.3
Discount 6% 95,518,840.8 112,961,888.7
Discount 7% 92,519,652.9 109,428,770.9
Discount 8% 89,701,505.4 106,108,774.5Model Inputs
Baseline event rates
A meta-analysis study by Wang et al. [19] examined the effects of
amlodipine or ARBs in the prevention of stroke and MI in patients
with HTN, coronary artery disease, or diabetic nephropathy. The
study included 12 trials of 94,338 patients. Compared with ARBs,
amlodipine reduced the incidence of stroke and MI by 16% and 17%,
respectively, with better blood pressure control. Mortality risk in
stroke or MI survivors is 2.3 times higher than that in the general
population [20,21]. The rates are presented in Table 1. Mortality risk
in the general Chinese population by age group is presented in
Table 2 [27]. It is assumed that the risk of stroke or MI and the
mortality risk in each year of the 5-year time periodwill be the same.
Resource use and costs
Costs of managing MI hospitalization and follow-up medical care
cost during year 1 were obtained from China Health Statistics
Yearbook 2010, assuming 50% surgery and 50% nonsurgery
treatment (Table 1). For the costs of stroke management, we
identified 80 recent patients with stroke in three Chinese tertiary
hospitals to conduct a retrospective chart review project to
document the costs associated with the clinical management of
stroke during hospitalization. A detailed data exaction form was
designed to retrieve the data. In addition, telephone interviews
were conducted to identify the follow-up costs associated with
stroke management and recovery following hospital discharge
during year 1. The costs of managing MI or stroke survivors from
years 2 to 5 were assumed to be 10% of that of year 1.
Quality-of-life adjustment
To estimate QALYs, it was necessary to apply utility value to
adjust the quality for the average period of time of survival
within the time span of the model, using an appropriate utility or
preference score. We used the utility measured in a 2008 survey
in China for elderly population living without stroke or MI
(Table 1) [25]. Utility scores of poststroke or post-MI patients
were based on the values provided in a review study by Ara et al.
(Table 1) [26]. As shown in Table 1, different utility scores were
used for different age groups without stroke or MI; different
utility scores were used for the first year of a stroke or MI event
and the years after that.rs (QALYs), and incremental cost-effectiveness ratios
e yuan.
Total QALYs ICER
Amlodipine ARBs
29,019.4 28,900.7 Dominant
29,019.4 28,900.6 Dominant
29,069.8 28,944.9 Dominant
29,039.4 28,929.3 Dominant
28,995.5 28,870.4 Dominant
28,910.1 28,838.8 Dominant
32,485.5 32,353.9 Dominant
30,930.2 30,803.7 Dominant
26,721.9 26,623.6 Dominant
30,084.3 29,959.7 Dominant
29,541.6 29,420.0 Dominant
28,516.6 28,400.5 Dominant
28,032.2 27,918.9 Dominant
27,565.5 27,454.7 Dominant
27,115.5 27,007.2 Dominant
26,681.5 26,575.6 Dominant
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The base-case analyses were undertaken for a cohort at the age
of 65 years, and 50% were men, using valsartan’s cost (f2388
annually) as the ARB comparator.
A deterministic model was run with the value inputs of all
necessary parameters. The total costs in the ARB and amlodipine
arms during the 5-year time period were calculated and com-
pared. Separately, QALYs in the ARB and amlodipine arms during
the 5-year time period were calculated and compared.Results
Base-Case Analysis
Table 3 presents the base-case results for the duration of 5 years.
Amlodipine is dominant compared with ARBs. Total costs of the
amlodipine arm are f20,326,895.3 lower than those of the ARBs
arm, which is f2,032.7 lower per patient. QALYs of the amlodipine
arm are 127.8 (QALY) higher than those of the ARBs arm.
Alternative Scenarios
A series of sensitivity analyses was conducted to explore the
impact of alternative assumptions on the incremental cost-
effectiveness ratios for the values of key input parameters. The
following parameters and ranges were tested:1. Comparator in the ARB group: Irbesartan’s cost (f1950), which
is lower than that of valsartan, is used to replace valsartan;2. Percentage of male patients: The assumption of 50% was
changed to 30%, 40%, 60%, and 70%;3. Discount rate for cost and QALY: The base-case rate of 3% was
changed to 1%, 2%, 4%, 5%, 6%, 7%, and 8%.
The results of these analyses are shown in Table 4, which
demonstrates that the results are robust to the variables tested,
with the most sensitive parameter being the ARB comparator.
When irbesartan was used to replace valsartan in the compar-
ison, the cost difference between amlodipine and ARB changed
from f19,264,622.3 to f80,731.0. It should also be noted that
the total cost was more sensitive than total QALYs to the
sensitivity test. For example, when the discount rate was set at
1%, the total cost of the amlodipine arm changed from
f105,757,180.9 to f113,798,954.4 while the total QALYs changed
from 29,019.4 to 30,084.3. In conclusion, the cost saved by
amlodipine was sensitive to the various ARB comparators; the
total cost of both amlodipine and ARB is somewhat sensitive to
the change in the discount rate. But in all cases, amlodipine is
consistently dominant in all the scenarios, demonstrating the
robustness of the results.Discussion
Recent clinical evidence shows that new CCBs such as amlodi-
pine provide additional benefit than ARBs [19]. No published
studies have attempted to formally evaluate the relative cost-
effectiveness of amlodipine and ARBs in the Chinese setting. The
present study provides the first cost-effectiveness analysis com-
paring these two most popular classes of antihypertensive
medications currently available in the Chinese market.
The study showed that amlodipine is a cost-saving therapy
compared with ARBs for the management of HTN with lower
long-term cost and higher QALY gained.
This is mainly due to the greater clinical effectiveness of
amlodipine compared with ARBs in terms of stroke and MI
events. Patients using amlodipine have fewer hospitalizationsand invasive surgical procedures in both short and long term. It is
noted that the total cost was more sensitive than total QALYs
during sensitivity analyses. Although the cost saved by amlodi-
pine varied when compared with different ARB comparators and
with different discount rates, amlodipine is dominant in all the
scenarios. If more expensive ARB comparators (e.g., losartan) are
included in the model, amlodipine will still be dominant and the
cost saved with amlodipine will be even higher. Our findings in
the Chinese setting are consistent with pharmacoeconomics
studies in the US and European settings [28]. The review of those
studies suggests that amlodipine had better clinical outcome
with cost savings in the long term [28].
Some limitations of this study have been identified. Caution
should be taken to extrapolate our findings to the time period
longer than 5 years. The above results are subject to the price
change of amlodipine and/or ARBs. It should be noted that the
cost estimation of stroke management was based on patients
from the Chinese tertiary hospitals. The generalizability of the
findings to lower-tier hospitals should be examined in future
studies. Last, we did not include patients with both MI and stroke
in the model because of the lack of risk data; this may limit the
generalizability of this study. Given the complexity and higher
cost in managing such patients, however, the inclusion of such
patients is likely to show more cost saved by amlodipine.Conclusions
The present study found that compared with ARBs, amlodipine
provides better quality of life over the 5-year time period
projected. From a Chinese payer perspective, amlodipine is a
cost-saving therapy when compared with ARBs by lowering the
costs needed to manage acute stroke and MI episodes and related
long-term recovery.
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unrestricted grant from Pfizer.
R E F E R E N C E S[1] Kearney PM, Whelton M, Reynolds K, et al. Global burden of
hypertension: analysis of worldwide data. Lancet 2005;365:217–23.
[2] He J, Gu D, Chen J, et al. Premature deaths attributable to blood pressure
in China: a prospective cohort study. Lancet 2009;374(9703):1765–72.
[3] Xu T, Wang Y, Li W, et al. Survey of prevalence, awareness, treatment,
and control of hypertension among Chinese governmental and
institutional employees in Beijing. Clin Cardiol 2010;33(6):E66–72.
[4] Zhai Y, Hu JP, Kong LZ, et al. Economic burden of coronary heart disease
and stroke attributable to hypertension in China. Zhong Hua Liu Xing
Bing Xue Za Zhi 2006;27(9):744–7.
[5] Lawes CMM, Hoorn SV, Rodgers A. Global burden of blood-pressure-
related disease. Lancet 2008;371:1513–8.
[6] The Seventh Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure (Report
No. 04-5230). Bethesda, MD: National Heart, Lung, and Blood Institute,
2004.
[7] Liu L, Zhang Y, Liu G, et al. FEVER Study Group. The Felodipine Event
Reduction (FEVER) study: a randomized long-term placebo-controlled
trial in Chinese hypertensive patients. J Hypertens 2005;23:2157–72.
[8] Manjila S, Masri T, Shams T, et al. Evidence-based review of primary
and secondary ischemic stroke prevention in adults: a neurosurgical
perspective. Neurosurg Focus 2011;30(6):E1.
[9] Liu M, Wu B, Wang W, et al. Stroke in China: epidemiology, prevention,
and management strategies. Lancet Neurol 2007;6:456–64.
[10] Dubow J, Fink ME. Impact of hypertension on stroke. Curr Atheroscler
Rep Epub 2011, May 31. Available from: http://www.springerlink.com/
content/j046631q87265k43/. [Accessed January 9, 2013].
[11] Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel
compared with clopidogrel alone after recent ischaemic stroke or
transient ischaemic attack in high-risk patients (MATCH):
randomised, double-blind, placebo-controlled trial. Lancet
2004;364(9431):331–7.
VA L U E I N H E A LT H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 7 5 – 8 080[12] Barreras A, Turner CG. Angiotensin II receptor blockers. Proc (Bayl Univ
Med Cent) 2003;16:123–6.
[13] Lee PK, Li RK, Chan JC, et al. A prescription survey in a hospital
hypertension outpatient clinic. Br J Clin Pharmacol 1997;44(6):577–82.
[14] Wong MCS, Jiang JY, Lam AT, et al. Patterns of antihypertensive
prescribing, discontinuation and switching among a Hong Kong
Chinese population from over one million prescriptions. Hum
Hypertens 2008;22:714–6.
[15] Wu SY, Lung BC, Chang S, et al. Evaluation of drug usage and
expenditure in a hospital diabetes clinic. Clin Pharm Ther
1998;23:49–56.
[16] Chen WX, Tan X. A review of the utilization of oral calcium channel
blockers. Curr Pharm Today (Chinese) 2009;19:31–3.
[17] Zhang JF. Medication use among hypertension patients in a Chinese
hospital. China Pract Med 2009;5:111–2.
[18] Norvasc: therapeutical action and side effects. Available from: http://
www.cheapnorvasc.net/. [Accessed September 10, 2011].
[19] Wang JG, Li Y, Franklin SS, et al. Prevention of stroke and myocardial
infarction by amlodipine and angiotensin receptor blockers: a
quantitative overview. Hypertension 2007;50(1):181–8.
[20] Thorvaldsen P, Kuulasmaa K, Rajakangas AM, et al. Stroke trends in the
WHO MONICA project. Stroke 1997;28:500–6.[21] Jiang SL, Ji XP, Wang Y, et al. Impact of gender on in-hospital death in
hospitalized patients with acute myocardial infarction. Zhonghua Xin
Xue Guan Bing Za Zhi 2008;36:590–3.
[22] Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomes in
hypertensive patients at high cardiovascular risk treated with regimens
based on valsartan or amlodipine: the VALUE randomised trial. Lancet
2004;363:2022–31.
[23] National Bureau of Statistics of China. China Health Statistics Yearbook
2010. China Statistics Press, Beijing. 2011.
[24] Price Administration Bureau of Jinan. Available from: http://www.qpn.
gov.cn/guding/yychaxun/form.asp. [Accessed October 1, 2011].
[25] Sun S, Chen J, Johannesson M, et al. Population health status in China:
EQ-5D results, by age, sex and socio-economic status, from the
National Health Services Survey 2008. Qual Life Res 2011;20:309–20.
[26] Ara R, Tumur I, Pandor A, et al. Ezetimibe for the treatment of
hypercholesterolaemia: a systematic review and economic evaluation.
Health Technol Assess 2008;12:iii, xi–xiii, 1–212.
[27] The 5th China national population census. Available from: http://www.
stats.gov.cn/tjsj/ndsj/renkoupucha/2000pucha/html/t0604.htm.
[Accessed October 1, 2011].
[28] de Portu S, Mantovani LG. Amlodipine: a pharmacoeconomic review.
J Med Econ 2009;12:60–8.
